Bioxyne Limited · ASX:BXN
Bioxyne — Investor Presentation (June 2025)
14 slides from Bioxyne's investor presentation, Jun 19, 2025
Slide 1: Business Update & Progress Report
Business Update & Progress Report Australia’s leading manufacturer & wholesaler of novel medicines ASX:BXN Shareholder Presentation | June 2025
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this p
Slide 3: Presentation Guide
Presentation Guide 1. Australian Operations Performance 2. European Progress 3. UK Progress 4. MDMA Medicines Development 5. FY2025 Revenue Guidance Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 3
Slide 4: Australian Operations Update FY25
Australian Operations Update FY25 Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 4
Slide 5: Australia’s Leading Medical Cannabis Manufacturer
Australia’s Leading Medical Cannabis Manufacturer BXN has outperformed its growth forecasts over the last 12 months. In 2024 our goal was to become the leading medical cannabis manufacturer. Here are the results: >1 million ~15 million >12,000 KG Finished medicines individual pastilles in the last o
Slide 6: We work with 100+ companies in Australia
We work with 100+ companies in Australia ~100 B2B Clients ~$1,000,000 ~$280k Annual Sales Avg. Annual Order Value 33 Australian SKUs $3m Current run rate, sales/month 18 UK Registered 3 Sales Team Headcount (Aus) 16 Germany Registered 40 Operations Team Headcount (Aus) - 50% flexible contract Bioxyn
Slide 7: European Progress Report
European Progress Report Shareholder Presentation | June 2025 Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 7
Slide 8: Selling Tons to Europe
Selling Tons to Europe European Cannabis is a 200+ tons per year market opportunity Germany Czechia Other EU Markets 16 >140 TONS $500,000 Malta BfArM Product Registrations Cannabis Flower Market per Investment in EUGMP Flower Fcst Revenue from finished Submitted Year Packing facility planned in pro
Slide 9: UK Progress Report
UK Progress Report Shareholder Presentation | June 2025 Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 9
Slide 10: The UK is a sleeping giant
The UK is a sleeping giant Pastilles, Flower, Oils, Vape, Pessaries, Suppositories Pricing and quality arbitrage and limited local manufacturing automation or scale… ~80,000 4x 18 + ~A$2.5m Import and distribution BLS CBPMs registered Value of first shipment of Estimated medical cannabis partners in
Slide 11: Psychedelics Progress Update
Psychedelics Progress Update Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 11
Slide 12: Development of BLSMD40 and BLSMD100 MDMA
Development of BLSMD40 and BLSMD100 MDMA Capsules Complete & Commercially Ready BLSMD40 and BLSMD100 Capsules contain 40mg and 100mg of 3,4-Methylenedioxymethamphetamine Hydrochloride. 10kg + 10g 50g MDMA 500-1,250 Psilocybe Cubensis Fungi + 5000+ Imported in 2025 Patient Doses Synthetic Psilocybin
Slide 13: Revenue Guidance for FY25 (June)
Revenue Guidance for FY25 (June) Bioxyne | ASX:BXN | Investor Presentation | February 2025 | 13
Slide 14: FY25 Revenue Upgrade
FY25 Revenue Upgrade Target: Continued growth and maintaining profitability metrics Bioxyne revenues from operations ($000's) 30,000 $25m $28m 3,000 25,000 Previous Guidance Revised Guidance 20,000 15,000 25,000 10,000 - Profitable ~50% & Cashflow Positive for 5,000 - 9,325 FCST Gross Margin* - 5,16